Combining insulin with metformin in type II diabetes improves glycaemic control and prevents weight gain;Kombinationsbehandling med insulin och metformin vid typ 2-diabetes: Förbättrar blodglukoskontroll och motverkar viktuppgång

Lakartidningen

Volumn 96, Issue 50, 1999, Pages 5616-5619

  Hermann, Leif Sparre ^a,c   Melander, Arne ^b  

^a Meda AB ^*  (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c Meda AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN; METFORMIN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; WEIGHT GAIN;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; METFORMIN; WEIGHT GAIN;

EID: 0033572084     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Attvall S. Övergång till insulin vid tablettsvikt - ett förslag på handläggning. Diabetolog Nytt 1997; 3: 25-7.
2. Tovi J. Insulin treatment of elderly type 2 diabetic patients [dissertation]. Stockholm Karolinska institutet, 1998.
3. Clauson P, Efendic S. Behandling av typ 2-diabetes. Viktigt med tidigare upptäckt av sekundärsvikt vid tablettbehandling. Läkartidningen 1999; 96: 176-81.
4. Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992; 15: 737-54.
5. Hermann LS. Clinical pharmacology of biguanides. In: Kuhlmann J, Puls W, eds. Oral antidiabetics. Handbook of experimental pharmacology. Berlin: Springer Verlag, 1996: 373-407.
6. Hermann LS. Combination therapy with insulin and metformin. Endocrine Practice 1998; 4: 404-12.
7. Hermann LS. Metformin as monotherapy and combined with glibenclamide in patients with non-insulin dependent diabetes mellitus [dissertation]. Lund University. Lund: Studentlitteratur, 1994.
8. Leblanc H, Marre M, Billault B, Passa P. Intéret de l'association infusion souscutanée d'insuline et metformine chez 10 diabétique insulino-nécessitants obèses. Diabetes Metab 1987; 13: 613-7.
9. Giugliano D, Quatraro A, Consoli G, Minei A, Ceriello A, DeRosa N. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 1993; 44: 107-12.
10. Gin H, Messerschmitt C, Brottier E, Aubertin J. Metformin improved insulin resistance in type I, insulin-dependent diabetic patients. Metabolism 1975; 34: 923-5.
11. Bailey CJ, Turner RC. Metformin. N Eng J Med 1996; 334: 574-9.
12. Wiernsperger N. Preclinical pharmacology of biguanides. In: Kuhlmann J, Puls W, eds. Oral antidiabetics. Handbook of experimental pharmacology. Berlin: Springer-Verlag, 1996: 305-58.
13. Gregorio F, Ambrosi F, Angelici F, Christallini S, Dini FL, Vespasiani G et al. Indice di massa corporea, lattato ematico ed efficacia terapeutica della metformina nel diabete di tipo II. Medicina Riv EMI 1989; 9: 200-4.
14. Golay A, Guille-Dauphiné N, Fendel A, Juge C, Assal JP. The insulin-sparing effect of metformin in insulin-treated diabetic patients. Diabetes Metab Rev 1995; 11: S63-S67.
15. Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care 1998; 21: 701-5.
16. Chow CC, Tsang LWW, Sorensen JP, Cockram CS. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care 1995; 18: 307-14.
17. Yki-Järvinen H, Nikkilä K, Ryysy L, Tulokas T, Vanamo R, Heikkilä M. Comparison of bed-time insulin regimens in NIDDM: Metformin precents insulininduced weight gain. Diabetologia 1996; 39 suppl 1: A33.
18. Yki-Järvinen H, Ryysy L, Nikkilä K, Tulokas T, Vanamo R, Heikkilä M. Comparison of bed-time insulin regimens in patients with type 2-diabetes mellitus. A randomized controlled trial. Ann Intern Med 1999; 130: 389-96.
19. Gardner DW, Griffing GT, Hamdy O. Triple therapy of metformin, sulfonylurea, and insulin in type II diabetic. J Investig Med 1995; 43 suppl 3: 461 A.
20. Schnack C, Biesenbach G, Kacerovsky G, Mihaljevic R, Pecnik I, Pieber T et al. Evaluation of optimal therapy in type-2 diabetic patients insufficiently treated with sulfonylureas: The Austrian insulin intervention study. Diabetologia 1996; 39 suppl 1: A33.
21. Van der Waal PS, Scheen A, vanGaal L, Schmitt H, Heine RJ and the SWIM Study Group. Efficacy of bedtime NPH insulin alone, as compared to combination with metformin and/or glipizide in NIDDM patients with secondary failure to oral hypoglycemic agents. Diabetes 1996; 45 suppl 2: 286A.
22. McNulty SJ, Mangnall M, Benbow SJ, Hardy KJ. Metformin versus gliclazide in combination with daily NPH insulin in poorly controlled Type 2 diabetic patients: 1-2 year follow-up data. Diabet Med 1998; 15 suppl 1:S9.
23. Bell DSH. Reinitiation of oral hypoglycemic therapy. The Alabama experience. In: Baylor College of Medicine, eds. Proceedings of the combined insulin/oral agent therapy: Satellite symposium th the 1997 postgraduate meeting. Houston, Texas, USA: Adis International, 1997:29-33.
24. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
25. Turner RC, Holman R, Stratton I. The UK prospective diabetes study (correspondence - authors reply). Lancet 1998; 352: 1932-4.